These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Generation and evaluation of reassortant influenza vaccines made by reverse genetics for H9N2 avian influenza in Korea. Song JM; Lee YJ; Jeong OM; Kang HM; Kim HR; Kwon JH; Kim JH; Seong BL; Kim YJ Vet Microbiol; 2008 Aug; 130(3-4):268-76. PubMed ID: 18374520 [TBL] [Abstract][Full Text] [Related]
34. A one-size-fits-all flu vaccine? Kaiser J Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732 [No Abstract] [Full Text] [Related]
35. Should vaccines and antiviral therapy for influenza now be deployed strategically? Griffiths PD Rev Med Virol; 2004; 14(3):137-9. PubMed ID: 15124230 [No Abstract] [Full Text] [Related]
36. Cell culture–derived influenza vaccines: has their time come? Bernstein DI Clin Infect Dis; 2010 Nov; 51(9):1005-6. PubMed ID: 20868285 [No Abstract] [Full Text] [Related]
37. How to flee the flu. Junker AK; Bonilla FA; Sullivan KE Clin Immunol; 2004 Sep; 112(3):219-20. PubMed ID: 15308112 [No Abstract] [Full Text] [Related]
38. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development? O'Hagan DT; Wack A; Podda A Clin Pharmacol Ther; 2007 Dec; 82(6):740-4. PubMed ID: 17971820 [TBL] [Abstract][Full Text] [Related]
40. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]